The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia
Open accessAbstract
AIMS: This randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of ezetimibe 10 mg/day in patients with primary hypercholesterolemia. METHODS AND RESULTS: Following dietary stabilization, a 2-12-week washout period, and a 4-week, single-blind, placebo lead-in period, 827 patients with baseline low-density lipoprotein cholesterol (LDL-C) > or =3.36 mmol/l (130 mg/dl) to < or =6.47 mmol/l (250 mg/dl) and triglycerides < or =3.95 mmol/l (350 mg/dl) were randomized 3:1 to receive ezetimibe 10 mg or placebo orally once daily in the morning for 12 weeks. The primary efficacy endpoint was percentage reduction in direct plasma LDL-C. Ezetimibe reduced direct LDL-C by a mean of 17.7% from baseline to endpoint, compared with an increase of 0.8% with placebo (P<0.01). Response to ezetimibe was generally consistent across all subgroups analyzed. Ezetimibe also significantly improved levels of plasma total cholesterol, apolipoprotein B, high-density lipoprotein(2)-cholesterol and lipoprotein(a), and elicited a trend toward lower triglyceride levels. Ezetimibe did not alter the serum concentrations of lipid-soluble vitamins or significantly affect baseline or stimulated cortisol production. Ezetimibe was well tolerated, with a safety profile similar to that of placebo. CONCLUSIONS: Ezetimibe, which significantly reduces LDL-C and favorably affects other lipid variables, may provide a well tolerated and effective new option for lipid management in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1984) · JAMA · doi:10.1001/jama.251.3.365 · Cited by 643
Van Heek, M., Farley, C., Compton, D. S., Hoos, L., Alton, K. B., Sybertz, E. J., & Davis, H. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703235 · Cited by 326
Bays, H. E., Moore, P. B., Drehobl, M. A., Rosenblatt, S., Toth, P. D., Dujovne, C. A., Knopp, R. H., Lipka, L. J., LeBeaut, A. P., Yang, B., et al. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80102-8 · Cited by 311
Self-citationDavidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., & Burke, S. K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1893 · Cited by 307
Van Heek, M., France, C. F., Compton, D. S., Mcleod, R. L., Yumibe, N. P., Alton, K. B., Sybertz, E. J., & Davis, H. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36992-7 · Cited by 305
Van Heek, M., Farley, C., Compton, D. S., Hoos, L., & Davis, H. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704260 · Cited by 218
Diseases of the heart and blood vessels
Satterthwaite, T. E. (1913) · Medical Entomology and Zoology · Cited by 202
Defining patient risks from expanded preventive therapies
Tolman, K. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00946-2 · Cited by 98
Cited by
Iqbal, J., & Hussain, M. M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90899.2008 · Cited by 811
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Narrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Metadata
- Authors
- Knopp, R.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04
- Volume
- 24
- Issue
- 8
- Pages
- 729-741
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2163252871
- Cited by
- 401
- References
- 14
- FWCI
- 35.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. https://app.cochat.ai/papers/10.1016/s0195-668x(02)00807-2
- The paper
- Knopp, R. (2003). Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. European Heart Journal. https://doi.org/10.1016/s0195-668x(02)00807-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.